324 related articles for article (PubMed ID: 27571409)
1. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
3. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
Robinson TJ; Liu JC; Vizeacoumar F; Sun T; Maclean N; Egan SE; Schimmer AD; Datti A; Zacksenhaus E
PLoS One; 2013; 8(11):e78641. PubMed ID: 24265703
[TBL] [Abstract][Full Text] [Related]
4. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis.
Zacksenhaus E; Shrestha M; Liu JC; Vorobieva I; Chung PED; Ju Y; Nir U; Jiang Z
Trends Cancer; 2017 Nov; 3(11):768-779. PubMed ID: 29120753
[TBL] [Abstract][Full Text] [Related]
6. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
7. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
[TBL] [Abstract][Full Text] [Related]
8. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
9. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.
Jiang Z; Jones R; Liu JC; Deng T; Robinson T; Chung PE; Wang S; Herschkowitz JI; Egan SE; Perou CM; Zacksenhaus E
Cell Cycle; 2011 May; 10(10):1563-70. PubMed ID: 21502814
[TBL] [Abstract][Full Text] [Related]
10. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
11. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R; Gulati A; Haider S; Kumar R; Campbell J; Knudsen E; Pettitt SJ; Ryan CJ; Lord CJ
Oncogene; 2018 Oct; 37(43):5701-5718. PubMed ID: 29915391
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
13. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
14. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
15. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
16. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
17. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract][Full Text] [Related]
18. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
19. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
20. Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
Zhang X; Pang X; Zhang Z; Liu Q; Zhang H; Xiang Q; Cui Y
BMC Cancer; 2021 Sep; 21(1):1026. PubMed ID: 34525987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
